COVID-19 Vaccine Market (Vaccine Type: mRNA, Viral Vector Vaccines (Adenovirus Vaccines, Inactivated Virus Vaccines, and Others), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
COVID-19 Vaccine Market – Scope of Report
TMR’s report on the global COVID-19 vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global COVID-19 vaccine market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 vaccine market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the COVID-19 vaccine market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global COVID-19 vaccine market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global COVID-19 vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global COVID-19 vaccine market.
The report delves into the competitive landscape of the global COVID-19 vaccine market. Key players operating in the global COVID-19 vaccine market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 vaccine market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market COVID-19 vaccine.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
- Industry Sources:
- WorldWideScience.org
- Elsevier, Inc.
- National Institutes of Health (NIH)
- PubMed
- NCBI
- Department of Health Care Service
- Trade Data Sources
- Trade Map
- UN Comtrade
- Trade Atlas
- Company Information
- OneSource Business Browser
- Hoover’s
- Factiva
- Bloomberg
- Mergers & Acquisitions
- Thomson Mergers & Acquisitions
- MergerStat
- Profound
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global COVID-19 Vaccine Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. COVID-19 vaccine Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global COVID-19 Vaccine Market Analysis and Forecast, 2017–2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 5. Market Outlook
- 5.1. Disease incidence and prevalence across the globe
- 5.2. Analysis of COVID-19 vaccination across the globe
- 5.3. Regulatory scenario across the globe/key countries
- 6. Global COVID-19 Vaccine Market Analysis and Forecast, by Vaccine Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Vaccine Type, 2017–2031
- 6.3.1. mRNA
- 6.3.2. Viral Vector Vaccines
- 6.3.2.1. Inactivated Virus Vaccines
- 6.3.2.2. Adenovirus Vaccines
- 6.3.2.3. Others
- 6.3.3. Others
- 6.4. Market Attractiveness, by Vaccine Type
- 7. Global COVID-19 Vaccine Market Analysis and Forecast, by Age Group
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Age Group, 2017–2031
- 7.3.1. 12 to 18
- 7.3.2. Above 18
- 7.4. Market Attractiveness, by Age Group
- 8. Global COVID-19 Vaccine Market Analysis and Forecast, by Distribution Channel
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by Distribution Channel, 2017–2031
- 8.3.1. Government Entities
- 8.3.2. Hospitals and Clinics
- 8.3.3. Others
- 8.4. Market Attractiveness, by Distribution Channel
- 9. Global COVID-19 Vaccine Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness, by Country/Region
- 10. North America COVID-19 Vaccine Market Analysis and Forecast
- 10.1. Introduction
- 10.1.1. Key Findings
- 10.2. Market Value Forecast, by Vaccine Type, 2017–2031
- 10.2.1. mRNA
- 10.2.2. Viral Vector Vaccines
- 10.2.2.1. Inactivated Virus Vaccines
- 10.2.2.2. Adenovirus Vaccines
- 10.2.2.3. Others
- 10.2.3. Others
- 10.3. Market Value Forecast, by Age Group, 2017–2031
- 10.3.1. 12 to 18
- 10.3.2. Above 18
- 10.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 10.4.1. Government Entities
- 10.4.2. Hospitals and Clinics
- 10.4.3. Others
- 10.5. Market Value Forecast, by Country, 2017–2031
- 10.5.1. U.S.
- 10.5.2. Canada
- 10.6. Market Attractiveness Analysis
- 10.6.1. By Vaccine Type
- 10.6.2. By Age Group
- 10.6.3. By Distribution Channel
- 10.6.4. By Country
- 11. Europe COVID-19 Vaccine Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Vaccine Type , 2017–2031
- 11.2.1. mRNA
- 11.2.2. Viral Vector Vaccines
- 11.2.2.1. Viral Vector Vaccines
- 11.2.2.2. Adenovirus Vaccines
- 11.2.2.3. Others
- 11.2.3. Others
- 11.3. Market Value Forecast, by Age Group, 2017–2031
- 11.3.1. 12 to 18
- 11.3.2. Above 18
- 11.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 11.4.1. Government Entities
- 11.4.2. Hospitals and Clinics
- 11.4.3. Others
- 11.5. Market Value Forecast, by Country, 2017–2031
- 11.5.1. U.K.
- 11.5.2. Germany
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
- 11.6.1. By Vaccine Type
- 11.6.2. By Age Group
- 11.6.3. By Distribution Channel
- 11.6.4. By Country
- 12. Asia Pacific COVID-19 Vaccine Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Vaccine Type, 2017–2031
- 12.2.1. mRNA
- 12.2.2. Viral Vector Vaccines
- 12.2.2.1. Inactivated Virus Vaccines
- 12.2.2.2. Adenovirus Vaccines
- 12.2.2.3. Others
- 12.2.3. Others
- 12.3. Market Value Forecast, by Age Group, 2017–2031
- 12.3.1. 12 to 18
- 12.3.2. Above 18
- 12.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 12.4.1. Government Entities
- 12.4.2. Hospitals and Clinics
- 12.4.3. Others
- 12.5. Market Value Forecast, by Country, 2017–2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Rest of Asia Pacific
- 12.6. Market Attractiveness Analysis
- 12.6.1. By Vaccine Type
- 12.6.2. By Age Group
- 12.6.3. By Distribution Channel
- 12.6.4. By Country
- 13. Latin America COVID-19 Vaccine Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Vaccine Type, 2017–2031
- 13.2.1. mRNA
- 13.2.2. Viral Vector Vaccines
- 13.2.2.1. Inactivated Virus Vaccines
- 13.2.2.2. Adenovirus Vaccines
- 13.2.2.3. Others
- 13.2.3. Others
- 13.3. Market Value Forecast, by Age Group, 2017–2031
- 13.3.1. 12 to 18
- 13.3.2. Above 18
- 13.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 13.4.1. Government Entities
- 13.4.2. Hospitals and Clinics
- 13.4.3. Others
- 13.5. Market Value Forecast, by Country, 2017–2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
- 13.6.1. By Vaccine Type
- 13.6.2. By Age Group
- 13.6.3. By Distribution Channel
- 13.6.4. By Country
- 14. Middle East & Africa COVID-19 Vaccine Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Vaccine Type, 2017–2031
- 14.2.1. mRNA
- 14.2.1.1. Inactivated Virus Vaccines
- 14.2.1.2. Adenovirus Vaccines
- 14.2.1.3. Others
- 14.2.2. Viral Vector Vaccines
- 14.2.3. Others
- 14.3. Market Value Forecast, by Age Group, 2017–2031
- 14.3.1. 12 to 18
- 14.3.2. Above 18
- 14.4. Market Value Forecast, by Distribution Channel, 2017–2031
- 14.4.1. Government Entities
- 14.4.2. Hospitals and Clinics
- 14.4.3. Others
- 14.5. Market Value Forecast, by Country, 2017–2031
- 14.5.1. GCC countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Vaccine Type
- 14.6.2. By Age Group
- 14.6.3. By Distribution Channel
- 14.6.4. By Country
- 15. Competition Landscape
- 15.1. Market Player – Competition Matrix (by Tier and Size of Companies)
- 15.2. Market Share Analysis by Company (2021)
- 15.3. Company Profiles
- 15.3.1. Pfizer-BioNTech
- 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.1.2. Vaccine Type Portfolio
- 15.3.1.3. Financial Overview
- 15.3.1.4. SWOT Analysis
- 15.3.1.5. Strategic Overview
- 15.3.2. Moderna
- 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.2.2. Vaccine Type Portfolio
- 15.3.2.3. Financial Overview
- 15.3.2.4. SWOT Analysis
- 15.3.2.5. Strategic Overview
- 15.3.3. AstraZeneca
- 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.3.2. Vaccine Type Portfolio
- 15.3.3.3. Financial Overview
- 15.3.3.4. SWOT Analysis
- 15.3.3.5. Strategic Overview
- 15.3.4. Johnson & Johnson
- 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.4.2. Vaccine Type Portfolio
- 15.3.4.3. Financial Overview
- 15.3.4.4. SWOT Analysis
- 15.3.4.5. Strategic Overview
- 15.3.5. Sinovac
- 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.5.2. Vaccine Type Portfolio
- 15.3.5.3. Financial Overview
- 15.3.5.4. SWOT Analysis
- 15.3.5.5. Strategic Overview
- 15.3.6. Sinopharm
- 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.6.2. Vaccine Type Portfolio
- 15.3.6.3. Financial Overview
- 15.3.6.4. SWOT Analysis
- 15.3.6.5. Strategic Overview
- 15.3.7. Bharat Biotech
- 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.7.2. Vaccine Type Portfolio
- 15.3.7.3. Financial Overview
- 15.3.7.4. SWOT Analysis
- 15.3.7.5. Strategic Overview
- 15.3.8. Serum Institute of India
- 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.8.2. Vaccine Type Portfolio
- 15.3.8.3. Financial Overview
- 15.3.8.4. SWOT Analysis
- 15.3.8.5. Strategic Overview
- 15.3.9. Novavax
- 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.9.2. Vaccine Type Portfolio
- 15.3.9.3. Financial Overview
- 15.3.9.4. SWOT Analysis
- 15.3.9.5. Strategic Overview
- 15.3.10. Gamaleya Research Institute
- 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.10.2. Vaccine Type Portfolio
- 15.3.10.3. Financial Overview
- 15.3.10.4. SWOT Analysis
- 15.3.10.5. Strategic Overview
- 15.3.11. CanSino Biologics
- 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.11.2. Vaccine Type Portfolio
- 15.3.11.3. Financial Overview
- 15.3.11.4. SWOT Analysis
- 15.3.11.5. Strategic Overview
- 15.3.12. CureVac
- 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.12.2. Vaccine Type Portfolio
- 15.3.12.3. Financial Overview
- 15.3.12.4. SWOT Analysis
- 15.3.12.5. Strategic Overview
- 15.3.13. GlaxoSmithKline
- 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.13.2. Vaccine Type Portfolio
- 15.3.13.3. Financial Overview
- 15.3.13.4. SWOT Analysis
- 15.3.13.5. Strategic Overview
- 15.3.14. Sanofi-GSK
- 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.14.2. Vaccine Type Portfolio
- 15.3.14.3. Financial Overview
- 15.3.14.4. SWOT Analysis
- 15.3.14.5. Strategic Overview
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook